nucleofection buffer Search Results


amaxa p3 nucleofection buffer  (Lonza)
90
Lonza amaxa p3 nucleofection buffer
Amaxa P3 Nucleofection Buffer, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pmc08408593-260-8-11?v=Lonza
Average 90 stars, based on 1 article reviews
amaxa p3 nucleofection buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
circulating cd34 + cells from pooled healthy human donors  (Lonza)
90
Lonza circulating cd34 + cells from pooled healthy human donors
Circulating Cd34 + Cells From Pooled Healthy Human Donors, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pmc03755588-121-18-20?v=Lonza
Average 90 stars, based on 1 article reviews
circulating cd34 + cells from pooled healthy human donors - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
human stem cell nucleofection buffer  (Lonza)
90
Lonza human stem cell nucleofection buffer
Human Stem Cell Nucleofection Buffer, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/bio_rxiv__342311-27-18-23?v=Lonza
Average 90 stars, based on 1 article reviews
human stem cell nucleofection buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
amaxa t cell nucleofection buffer  (Lonza)
90
Lonza amaxa t cell nucleofection buffer
Amaxa T Cell Nucleofection Buffer, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pm32398348-221-17-21?v=Lonza
Average 90 stars, based on 1 article reviews
amaxa t cell nucleofection buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
amaxa nucleofection buffer  (Lonza)
90
Lonza amaxa nucleofection buffer
Amaxa Nucleofection Buffer, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pmc06181325-58-11-13?v=Lonza
Average 90 stars, based on 1 article reviews
amaxa nucleofection buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nucleofection buffer human t cell nucleofector kit  (Lonza)
90
Lonza nucleofection buffer human t cell nucleofector kit
Nucleofection Buffer Human T Cell Nucleofector Kit, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pm32239644-366-16-21?v=Lonza
Average 90 stars, based on 1 article reviews
nucleofection buffer human t cell nucleofector kit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nucleofection sf buffer  (Lonza)
90
Lonza nucleofection sf buffer
Nucleofection Sf Buffer, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pmc10936194__mbio__02479___23___s0001-23-18-21?v=Lonza
Average 90 stars, based on 1 article reviews
nucleofection sf buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nucleofection kits (10 96-well plates and buffer) p3  (Lonza)
90
Lonza nucleofection kits (10 96-well plates and buffer) p3
KEY RESOURCES TABLE
Nucleofection Kits (10 96 Well Plates And Buffer) P3, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pmc10103147-4-1-0?v=Lonza
Average 90 stars, based on 1 article reviews
nucleofection kits (10 96-well plates and buffer) p3 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nucleofectortm device (lonza) msc-specific nucleofection buffer  (Lonza)
90
Lonza nucleofectortm device (lonza) msc-specific nucleofection buffer
KEY RESOURCES TABLE
Nucleofectortm Device (Lonza) Msc Specific Nucleofection Buffer, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pmc09636385-68-34-31?v=Lonza
Average 90 stars, based on 1 article reviews
nucleofectortm device (lonza) msc-specific nucleofection buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nucleofection buffer lonza kit r  (Lonza)
90
Lonza nucleofection buffer lonza kit r
KEY RESOURCES TABLE
Nucleofection Buffer Lonza Kit R, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pm39919177-189-14-14?v=Lonza
Average 90 stars, based on 1 article reviews
nucleofection buffer lonza kit r - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nucleofection buffer human monocyte nucleofection kit  (Lonza)
90
Lonza nucleofection buffer human monocyte nucleofection kit
a . Cas9 gRNAs were designed to flank the chr21q22 enhancer region at the indicated sites. b . Representative bioanalyzer trace of PCR-amplified target region following monocyte CRISPR/Cas9 editing with an equimolar mix of RNPs containing 5′ and 3′ chr21q22 gRNAs. Example editing efficiency calculation shown. c . Editing efficiency at the chr21q22 locus. Mean enhancer deletion: 42.4% (n = 11). d . Location and sequence of gRNAs used to disrupt ETS2 . e . ETS2 editing efficiency. gRNA1 (mean), 89.7% (n = 31); gRNA2 (mean), 78.6% (n = 14). f . ETS2 expression (relative to NTC) following CRISPR/Cas9 editing, measured by qPCR (housekeeping gene PPIA ; equivalent results with other housekeeping genes; n = 10). g . Viability following monocyte <t>nucleofection</t> with Cas9 RNPs and macrophage differentiation. Mean values: NTC, 97.9%; gRNA1: 98.3%; gRNA2, 98.6% (n = 6). h . Expression of myeloid lineage markers following ETS2 editing and TPP differentiation (n = 5). Gating strategy shown in Supplementary Information Fig. . i . GSVA enrichment scores for 67 different monocyte/macrophage activation conditions to identify stimuli that phenocopy CD14+ monocytes/macrophages from IBD patients. j . Chromatin accessibility in ETS2-edited versus unedited inflammatory macrophages (n = 3). k . Enhancer activity (H3K27ac) in ETS2-edited versus unedited inflammatory macrophages (n = 3). P values calculated using edgeR (two-sided) in j , k . Red points denote adjusted P -value (P adj ) < 0.1, grey points NS. Error bars are mean±SEM in c , e - h . * P < 0.05. NTC: non-targeting control.
Nucleofection Buffer Human Monocyte Nucleofection Kit, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/pmc11168933-253-20-24?v=Lonza
Average 90 stars, based on 1 article reviews
nucleofection buffer human monocyte nucleofection kit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
lonza nucleofection buffer  (Lonza)
90
Lonza lonza nucleofection buffer
a . Cas9 gRNAs were designed to flank the chr21q22 enhancer region at the indicated sites. b . Representative bioanalyzer trace of PCR-amplified target region following monocyte CRISPR/Cas9 editing with an equimolar mix of RNPs containing 5′ and 3′ chr21q22 gRNAs. Example editing efficiency calculation shown. c . Editing efficiency at the chr21q22 locus. Mean enhancer deletion: 42.4% (n = 11). d . Location and sequence of gRNAs used to disrupt ETS2 . e . ETS2 editing efficiency. gRNA1 (mean), 89.7% (n = 31); gRNA2 (mean), 78.6% (n = 14). f . ETS2 expression (relative to NTC) following CRISPR/Cas9 editing, measured by qPCR (housekeeping gene PPIA ; equivalent results with other housekeeping genes; n = 10). g . Viability following monocyte <t>nucleofection</t> with Cas9 RNPs and macrophage differentiation. Mean values: NTC, 97.9%; gRNA1: 98.3%; gRNA2, 98.6% (n = 6). h . Expression of myeloid lineage markers following ETS2 editing and TPP differentiation (n = 5). Gating strategy shown in Supplementary Information Fig. . i . GSVA enrichment scores for 67 different monocyte/macrophage activation conditions to identify stimuli that phenocopy CD14+ monocytes/macrophages from IBD patients. j . Chromatin accessibility in ETS2-edited versus unedited inflammatory macrophages (n = 3). k . Enhancer activity (H3K27ac) in ETS2-edited versus unedited inflammatory macrophages (n = 3). P values calculated using edgeR (two-sided) in j , k . Red points denote adjusted P -value (P adj ) < 0.1, grey points NS. Error bars are mean±SEM in c , e - h . * P < 0.05. NTC: non-targeting control.
Lonza Nucleofection Buffer, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nucleofection+buffer/bio_rxiv__2025__07__16__664824-218-21-21?v=Lonza
Average 90 stars, based on 1 article reviews
lonza nucleofection buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


KEY RESOURCES TABLE

Journal: Cell

Article Title: Structural basis for Cas9 off-target activity

doi: 10.1016/j.cell.2022.09.026

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Lonza Nucleofection Kits (10 96-well plates and buffer) P3 , Lonza Walkersville, Inc. , Cat# V4SP-3960.

Techniques: Recombinant, DNA Extraction, Cell Isolation, Cell Culture, Ligation, Crystallization Assay, Software

KEY RESOURCES TABLE

Journal: Cell

Article Title: Structural basis for Cas9 off-target activity

doi: 10.1016/j.cell.2022.09.026

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Lonza Nucleofection Kits (10 96-well plates and buffer) P3 , Lonza Walkersville, Inc. , Cat# V4SP-3960.

Techniques: Recombinant, DNA Extraction, Cell Isolation, Cell Culture, Ligation, Crystallization Assay, Software

a . Cas9 gRNAs were designed to flank the chr21q22 enhancer region at the indicated sites. b . Representative bioanalyzer trace of PCR-amplified target region following monocyte CRISPR/Cas9 editing with an equimolar mix of RNPs containing 5′ and 3′ chr21q22 gRNAs. Example editing efficiency calculation shown. c . Editing efficiency at the chr21q22 locus. Mean enhancer deletion: 42.4% (n = 11). d . Location and sequence of gRNAs used to disrupt ETS2 . e . ETS2 editing efficiency. gRNA1 (mean), 89.7% (n = 31); gRNA2 (mean), 78.6% (n = 14). f . ETS2 expression (relative to NTC) following CRISPR/Cas9 editing, measured by qPCR (housekeeping gene PPIA ; equivalent results with other housekeeping genes; n = 10). g . Viability following monocyte nucleofection with Cas9 RNPs and macrophage differentiation. Mean values: NTC, 97.9%; gRNA1: 98.3%; gRNA2, 98.6% (n = 6). h . Expression of myeloid lineage markers following ETS2 editing and TPP differentiation (n = 5). Gating strategy shown in Supplementary Information Fig. . i . GSVA enrichment scores for 67 different monocyte/macrophage activation conditions to identify stimuli that phenocopy CD14+ monocytes/macrophages from IBD patients. j . Chromatin accessibility in ETS2-edited versus unedited inflammatory macrophages (n = 3). k . Enhancer activity (H3K27ac) in ETS2-edited versus unedited inflammatory macrophages (n = 3). P values calculated using edgeR (two-sided) in j , k . Red points denote adjusted P -value (P adj ) < 0.1, grey points NS. Error bars are mean±SEM in c , e - h . * P < 0.05. NTC: non-targeting control.

Journal: Nature

Article Title: A disease-associated gene desert directs macrophage inflammation through ETS2

doi: 10.1038/s41586-024-07501-1

Figure Lengend Snippet: a . Cas9 gRNAs were designed to flank the chr21q22 enhancer region at the indicated sites. b . Representative bioanalyzer trace of PCR-amplified target region following monocyte CRISPR/Cas9 editing with an equimolar mix of RNPs containing 5′ and 3′ chr21q22 gRNAs. Example editing efficiency calculation shown. c . Editing efficiency at the chr21q22 locus. Mean enhancer deletion: 42.4% (n = 11). d . Location and sequence of gRNAs used to disrupt ETS2 . e . ETS2 editing efficiency. gRNA1 (mean), 89.7% (n = 31); gRNA2 (mean), 78.6% (n = 14). f . ETS2 expression (relative to NTC) following CRISPR/Cas9 editing, measured by qPCR (housekeeping gene PPIA ; equivalent results with other housekeeping genes; n = 10). g . Viability following monocyte nucleofection with Cas9 RNPs and macrophage differentiation. Mean values: NTC, 97.9%; gRNA1: 98.3%; gRNA2, 98.6% (n = 6). h . Expression of myeloid lineage markers following ETS2 editing and TPP differentiation (n = 5). Gating strategy shown in Supplementary Information Fig. . i . GSVA enrichment scores for 67 different monocyte/macrophage activation conditions to identify stimuli that phenocopy CD14+ monocytes/macrophages from IBD patients. j . Chromatin accessibility in ETS2-edited versus unedited inflammatory macrophages (n = 3). k . Enhancer activity (H3K27ac) in ETS2-edited versus unedited inflammatory macrophages (n = 3). P values calculated using edgeR (two-sided) in j , k . Red points denote adjusted P -value (P adj ) < 0.1, grey points NS. Error bars are mean±SEM in c , e - h . * P < 0.05. NTC: non-targeting control.

Article Snippet: Cas9–gRNA ribonucleoproteins were assembled as described previously and nucleofected into 5 × 10 6 monocytes in 100 μl nucleofection buffer (Human Monocyte Nucleofection Kit, Lonza) using a Nucleofector 2b (Lonza, program Y-001).

Techniques: Amplification, CRISPR, Sequencing, Expressing, Activation Assay, Activity Assay, Control